osocimab subcutaneous (BAY 1213790 SC) / Bayer, Ligand - LARVOL DELTA

Factor XI Inhibitors for Preventing Postoperative Venous Thromboembolism in Patients Undergoing Elective Total Knee Arthroplasty: A Network Meta-analysis of Randomized Controlled Trials. (ISTH 2026) - "The NMA compared the following Factor XI inhibitor regimens: oral milvexian (25, 50, or 200 mg once daily; 25, 50, 100, or 200 mg twice daily), intravenous abelacimab (30, 75, or 150 mg single dose), intravenous osocimab (0.3, 0.6, 1.2, or 1.8 mg/kg postoperative; 0.3 or 1.8 mg/kg preoperative), subcutaneous FXI-ASO (200 or 300 mg preoperative), and intravenous REGN7508 (250 mg) or REGN9933 (300 mg), against enoxaparin (40 mg once daily). However, the lack of a significant reduction in symptomatic events warrants confirmation in larger phase 3 trials. Table or Figure Upload (1) Figure1 Page 2 Table or Figure Upload (2) Figure 2 DOI*10.1016/j.rpth.2026.103764"

Retrospective data • Cardiovascular • Hematological Disorders • Orthopedics • Venous Thromboembolism

Pharmacokinetics and pharmacodynamics of the factor XIa-inhibiting antibody osocimab in healthy male East Asian volunteers: Results from two phase 1 studies. (PubMed, Pharmacol Res Perspect) - "The effect of osocimab on aPTT was expected per its mechanism of action. Osocimab was generally well tolerated."

Clinical • Journal • P1 data • PK/PD data • Cardiovascular

CONVERT: Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (clinicaltrials.gov) - P2 | N=686 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Chronic Kidney Disease • Renal Disease

CONVERT: Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (clinicaltrials.gov) - P2; N=630; Active, not recruiting; Sponsor: Bayer; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Cardiovascular • Chronic Kidney Disease • Renal Disease

CONVERT: Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (clinicaltrials.gov) - P2; N=600; Recruiting; Sponsor: Bayer; Trial completion date: Nov 2022 ➔ Jul 2022; Trial primary completion date: Jul 2022 ➔ Feb 2022

Clinical • Trial completion date • Trial primary completion date • Cardiovascular • Chronic Kidney Disease • Renal Disease

CONVERT: Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (clinicaltrials.gov) - P2; N=600; Recruiting; Sponsor: Bayer; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Cardiovascular • Chronic Kidney Disease • Renal Disease

CONVERT: Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (clinicaltrials.gov) - P2; N=600; Not yet recruiting; Sponsor: Bayer

Clinical • New P2 trial • Cardiovascular • Chronic Kidney Disease • Renal Disease

Study to investigate the safety of a drug called osocimab at low and high doses in adult patients with kidney failure requiring regular hemodialysis (clinicaltrialsregister.eu) - P2; N=750; Ongoing; Sponsor: Bayer AG

Clinical • New P2 trial • Cardiovascular • Nephrology • Renal Disease